Corrigendum to "Tricyclic azepine derivatives: Pyrimido[4,5-b]-1,4-benzoxazepines as a novel class of epidermal growth factor receptor kinase inhibitors" [Bioorg. Med. Chem. Lett. 16 (2006) 1643-1646] (DOI:10.1016/j.bmcl.2005.12.018);Tricyclic azepine derivatives: Pyrimido[4,5-b]-1,4-benzoxazepines as a novel class of epidermal growth factor receptor kinase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 6, 2006, Pages 1643-1646

  Smith II, Leon ^a,b   Piatnitski, Evgueni L ^a   Kiselyov, Alexander S ^a,c   Ouyang, Xiaohu ^a   Chen, Xiaoling ^a   Burdzovic Wizemann, Sabina ^a   Xu, Yongjiang ^a   Wang, Ying ^a   Rosler, Robin L ^a   Patel, Sheetal N ^a   Chiang, Hui Hsien ^a   Milligan, Daniel L ^a   Columbus, John ^a   Wong, Wai C ^a   Doody, Jacqueline F ^a   Hadari, Yaron R ^a  

^a ELI LILLY AND COMPANY   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c CHEMDIV INC   (United States)

Author keywords

Benzoxazepine; Epidermal growth factor receptor; Kinase inhibitor; Kinase selectivity

Indexed keywords

AZEPINE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB;

ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN CELL; IN VIVO STUDY; PHOSPHORYLATION; STRUCTURE ACTIVITY RELATION;

EID: 32044458119     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.04.058     Document Type: Erratum

References (18)

1. P. Blume-Jensen, and T. Hunter Nature 411 2001 355
2. J. Mendelsohn, and J. Baselga Oncogene 19 2000 6550
3. J.S. de Bono, and E.K. Rowinsky Trends Mol. Med. 8 2002 19
4. J. Brabenber, K.D. Danenberg, R. Metzger, P.M. Schneider, J. Park, D. Salonga, D. Holscher, and P.V. Danenberg Clin. Cancer Res. 7 2001 1850
5. A. Bridges J. Chem. Rev. 101 2001 2541
6. M.W. Lee, C.W. Seo, S.W. Kim, H.J. Yang, H.W. Lee, J.H. Choi, K.C. Moon, and J.K. Koh Acta Derm. Venereol. 84 1 2004 23
7. N.B. Elkind, Z. Szentpetery, A. Apati, C. Ozvegy-Laczka, G. Varady, O. Ujhelly, K. Szabo, L. Homolya, A. Varadi, L. Buday, G. Keri, K. Nemet, and B. Sarkadi Cancer Res. 65 5 2005 1770
8. N. Van Zandwijk Br. J. Cancer 89 Suppl. 2 2003 S9
9. See Ref. 7 for EGFR enzymatic assay conditions.
10. 4 (50 μL/well) and absorbance was detected at 450 nm.
11. H.-R. Tsou, N. Mamuya, B.D. Johnson, M.F. Reich, B.C. Gruber, F. Ye, R. Nilakantan, R. Shen, C. Discafani, R. DeBlanc, R. Davis, F. Koehn, L.M. Greenberger, Y.-F. Wang, and A. Wissner J. Med. Chem. 44 2001 2719
12. L.G. Levkovskaya, N.V. Sazonov, N.A. Grineva, I.E. Mamaeva, L.A. Serochkina, and T.S. Safonova Khimiya Geterotsiklicheskikh Soedinenii 1 1985 122
13. J. Yang, X. Che, Q. Dang, Z. Wei, S. Gao, and X. Bai Org. Lett. 7 8 2005 1541
14. Smith II, L.; Hadari, Y. R. PCT Int. Appl. 2005009384, 2005.
15. 1H NMR and MS.
16. K.H. Gibson, W. Grundy, A.A. Godfrey, J.R. Woodburn, S.E. Ashton, B.J. Curry, L. Scarlett, A.J. Barker, and D.S. Brown Bioorg. Med. Chem. Lett. 7 21 1997 2723
17. G.W. Rewcastle, W.A. Denny, A.J. Bridges, H. Zhou, D.R. Cody, A. McMichael, and D.W. Fry J. Med. Chem. 38 1995 3482
18. W. Pan, H. Liu, Y.-J. Xu, X. Chen, K.H. Kim, D.L. Milligan, J. Columbus, Y.R. Hadari, P. Kussi, W.C. Wong, and M. Labelle Bioorg. Med. Chem. Lett. 15 2005 5474